Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

91.83
-6.9900-7.07%
Post-market: 91.830.00000.00%19:30 EDT
Volume:1.80M
Turnover:166.12M
Market Cap:5.96B
PE:-6.52
High:98.76
Open:98.76
Low:91.73
Close:98.82
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:2.36
T/O Rate:3.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-572.13
PE(LYR):-195.38

Loading ...

Mirum Pharmaceuticals Inc - Announces Primary Endpoint Met in Phase 2B Azure-1 Study of Brelovitug

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc - Primary Endpoint Achieved in Both Dose Arms at Week 24

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc - Topline Phase 3 Data From Azure-1 and Azure-4 Expected in H2 2026

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2B Portion of the Azure-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc: Favorable Safety and Tolerability Profiles Observed

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 24

Mirum Pharmaceuticals Price Target Maintained With a $132.00/Share by Citizens

Dow Jones
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), GeneDx Holdings (WGS) and Agios Pharma (AGIO)

TIPRANKS
·
Apr 21

Mirum director Saira Ramasastry disposes of USD 193,800 in common shares

Reuters
·
Apr 17

BRIEF-Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 14

Mirum grants inducement awards to 12 hires under 2020 plan

Reuters
·
Apr 14

Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Apr 10

Egetis appoints Tiago Nunes chief medical officer, replacing retiring Kristina Sjöblom Nygren

Reuters
·
Apr 09

Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Apr 09

Mirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?

Simply Wall St.
·
Apr 05

Assessing Mirum Pharmaceuticals (MIRM) Valuation After Record Revenues First GAAP Profitability And Key Trial Milestones

Simply Wall St.
·
Apr 04

Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi Year Surge?

Simply Wall St.
·
Mar 31

Mirum Pharmaceuticals Price Target Maintained With a $130.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 23